Epinephrine nasal spray potential and additional option for treating type 1 anaphylaxis

Epinephrine is the first-line treatment for managing severe allergic reactions, which is associated with lower hospitalization and death rates. However, current treatment options, such as epinephrine auto-injectors and manual intramuscular injections, are often considered inconvenient and challenging to use, even during severe reactions. To address this issue, an intranasal epinephrine delivery device called neffy has been developed as an alternative option.

This study assessed the comparative PK and PD of neffy 2.0 mg, EpiPen 0.3 mg, and manual intramuscular injection 0.3 mg. This study was a phase 1, randomized, 6-treatment, 6-period, 2-part crossover study conducted in 59 healthy subjects. PK and PD parameters were assessed before dosing and at various postdose intervals.

The mean maximum plasma concentrations with single doses of epinephrine for manual injection, neffy and EpiPen were 339 pg/ml, 481 pg/ml and 753 pg/ml, respectively. When dosed both once and twice, neffy had a more pronounced increase in pharmacodynamic parameters relative to EpiPen or manual injection.

They said that neffy's pharmacokinetic profile was bracketed by approved injection products, with PD responses comparable to or better than approved injection products.

They mentioned, "neffy is expected to be both a safe and effective option for those who are reluctant to carry and use injection devices."

This study was conducted in healthy volunteers, and this was the major limitation of this study. It is essential to evaluate epinephrine efficacy based on the available data with healthy volunteers and subjects with local allergic reactions, as well as with preclinical data and vast clinical experience.

Reference:

Casale, Thomas B., et al. “Pharmacokinetics/Pharmacodynamics of Epinephrine After Single and Repeat Administration of Neffy, EpiPen, and Manual Intramuscular Injection.” Journal of Allergy and Clinical Immunology, Elsevier BV, Aug. 2023. Crossref, https://doi.org/10.1016/j.jaci.2023.08.007.